Durvalumab - CAS 1428935-60-7

Durvalumab (MEDI 4736) is a humanized monoclonal antibody targeting PD-L1. It can block the interaction of PD-L1 with PD-1 and CD80, with IC50 values of 0.1 and 0.04 nM, respectively. Durvalumab is often used in combination with platinum-based compounds for the treatment of non-small cell lung cancer and advanced hepatocellular carcinoma cells.

PD-1/PD-L1

Apoptosis, Immunology/Inflammation, Cell Cycle/Checkpoint

1428868

0.972

-20°C

Ice Packs

Inhibitory Antibodies